DRUG NAME
Generic name:
Doxofylline
Brand name:
Ansimar
Therapeutic
Class:
Antiasthmatic
& COPD
Preparations
Dosage: Tab
Adult 1 tab
bid- tid. Syr
Children >12
yr 10 mL oncetid, <12 yrs 6-9
mg/kg bid
Form: Tablet400 mg; syrup100mg/5mL
MODE OF ACTION
INDICATION
 Adrenergic bronchodilators
 Bronchial
and phosphodiesterase
asthma &
inhibitors both work by
pulmonar
increasing intracellular level
y disease
of cyclic-3',5'- adenosine
w/ spastic
monophosphate (CAMP);
bronchial
adrenergics by increasing
compone
production and
nt.
phosphodiesterase inhibitors
by decreasing breakdown.
Increased levels of cAMP
produce bronchodilation.
Corticosteroids act by
decreasing airway
inflammation.
Anticholinergics (ipratropium)
produce brondhodilation by
decreasing intracellular levels
of cyclic guanosine
monophosphate (cGMP).
Leukotriene receptor
antagonists and mast cell
stabilizers decrease the
release of substances that
can contribute to
bronchospasm.
CONTRADICTION
 Acute MI,
hypotension,
lactation
 Special
Precaution:
Liver disease,
CHF, chronic
obstructive
lung disease,
concomitant
infections.
Pregnancy.
SIDE EFFECTS/ADVERSE
EFFECTS
 Nausea, vomiting,
epigastric pain,
cephalalgia, irritability,
insomnia, tachycardia,
extrasystole,
tachypnea,
hyperglycemia,
albuminuria.
NURSING INTERVENTIONS
 Assess lung sounds, pulse and
blood pressure before
administration and during peak
of medication. Not amount,
color, and character of sputum
produced.
 Monitor pulmonary function
tests before initiating therapy
and periodically during therapy
to determine effectiveness of
medication.
 Observe for paradoxical
bronchospasm (wheezing). If
conditions occur, withhold
medication and notify physician
of other health care
professional immediately.